Abstract
Meningioma is the most common primary intracranial tumor in adults. The grading of meningioma is based on World Health Organization criteria, which rely on histopathological features alone. This grading system is unable to conclusively predict the clinical behavior of these tumors (i.e., recurrence or prognosis in benign or atypical grades). Advances in molecular techniques over the last decade that include genomic and epigenomic data associated with meningiomas have been used to identify genetic biomarkers that can predict tumor behavior. This review summarizes the molecular characteristics of meningioma using genetic and epigenetic biomarkers. Molecular alterations that can predict meningioma behavior may be integrated into the upcoming World Health Organization grading system.
| Original language | English |
|---|---|
| Pages (from-to) | 45-63 |
| Number of pages | 19 |
| Journal | Journal of Pathology and Translational Medicine |
| Volume | 54 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Jan 2020 |
Bibliographical note
Publisher Copyright:© 2020 The Korean Society of Pathologists/The Korean Society for Cytopathology.
Keywords
- Meningioma
- Molecular diagnosis
- Pathological diagnosis
Fingerprint
Dive into the research topics of 'Molecular characteristics of meningiomas'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver